Document Detail

What is potent acid inhibition, and how can it be achieved?
MedLine Citation:
PMID:  16335854     Owner:  NLM     Status:  MEDLINE    
The clinical response to antisecretory treatment correlates directly with the degree of inhibition of acid secretion achieved. Acid inhibition able to maintain the intragastric pH at a value greater than 4 for at least 16 h/day seems to heal even the most refractory acid-related diseases. It has also been shown that the degree of inhibition of acid secretion in response to antisecretory treatment depends on the genetic characteristics of the patient and on the presence of Helicobacter pylori infection. A possible definition of potent (or profound) acid inhibition is, therefore, the achievement of the aforementioned level of control of acid secretion regardless of patient characteristics or of the presence of H. pylori infection. Antisecretory drugs differ in their ability to reach potent acid inhibition. As far as the comparative efficacy of different drugs for inhibiting acid secretion is concerned, proton pump inhibitors are more efficient in inhibiting gastric acid secretion than histamine (H2) receptor antagonists. Among the different proton pump inhibitors, esomeprazole 40 mg/day exhibits greater antisecretory potency than the others at standard doses. Rabeprazole 20 mg/day and lansoprazole 30 mg/day exhibit a more rapid onset of action than omeprazole 20 mg/day or pantoprazole 40 mg/day.
Xavier Calvet; Fernando Gomollón
Related Documents :
16710054 - Distinct mechanisms of acid-induced hco3- secretion in normal and slightly permeable st...
1629564 - Effects of bile acids and bilirubin on bicarbonate secretion of isolated guinea pig ant...
15470134 - Detection and masking of spoiled food smells by odor maps in the olfactory bulb.
8854204 - Comparative evaluation of the role of endogenous gastrin in basal acid secretion in con...
7684504 - In vitro study on the effects of fecal composition on fecapentaene kinetics in the larg...
22425514 - Harvesting of microalgae by flocculation with poly (γ-glutamic acid).
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  65 Suppl 1     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2005  
Date Detail:
Created Date:  2005-12-12     Completed Date:  2005-12-23     Revised Date:  2013-06-04    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  13-23     Citation Subset:  IM    
Digestive Diseases Unit, Sabadell Hospital, Parc Taulí University Institute, Autonomous University of Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Ulcer Agents / administration & dosage*
Benzimidazoles / administration & dosage
Clinical Trials as Topic
Esomeprazole Sodium
Gastric Acid / secretion*
Omeprazole / administration & dosage,  analogs & derivatives
Peptic Ulcer / drug therapy*
Proton Pumps / antagonists & inhibitors*
Sulfoxides / administration & dosage
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 0/Benzimidazoles; 0/Proton Pumps; 0/Sulfoxides; 103577-45-3/lansoprazole; 32828355LL/rabeprazole; 73590-58-6/Omeprazole; D8TST4O562/pantoprazole; L2C9GWQ43H/Esomeprazole Sodium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A pharmacological approach to gastric acid inhibition.
Next Document:  Optimising acid inhibition treatment.